| 1. |
|
|
| 2. |
|
|
| 3. |
- Gul, E., et al.
(författare)
-
Perspectives and state of the art in producing solar fuels and chemicals from CO2
- 2021
-
Ingår i: Advanced Technology for the Conversion of Waste into Fuels and Chemicals: Volume 2: Chemical Processes. - : Elsevier. - 9780323901505 ; , s. 181-219
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- Solar Fuels and chemicals from CO2 can be produced through two main reactions: one is CO2 photoreduction, using different catalysts and different reducing agents; the other is CO2 fixation, which is usually performed through natural photosynthesis. The research nowadays is directed on the production of fuels and chemicals with one or two atoms of carbon, for example CH4, CO, HCOOH, HCHO, CH3OH, C2H5OH, etc. The chapter aims at comparing natural photosynthesis processes and reactions with artificial photosynthesis. After taking into consideration the natural photosynthetic process, the chapter focuses on heterogeneous and homogeneous photocatalysis. Heterogeneous catalysis can be performed with semiconductors and powder catalysts. Special attention is given to TiO2 as a promising photocatalyst. Homogeneous photocatalysts are usually represented by molecular catalysts, which are dissolved in water or another solvent. Usually, homogeneous photocatalysis is performed in complex systems which are composed by: a light harvesting unit (LHU) (i.e. the photosensitizer); one catalytic site for the oxidation process, where the electrons are supplied by a sacrificial donor; one reduction site, where the electrons are transmitted to CO2. Finally, even more complex systems are represented by those based on photoelectrocatalysis. These have the main advantage to separate the oxidation and reduction reactions at the two different electrodes of the system. In principle photoelectrochemical cells can be a way to mimic artificially the working principle of natural photosynthesis.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Wimo, A, et al.
(författare)
-
An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial
- 2003
-
Ingår i: Dementia and geriatric cognitive disorders. - : S. Karger AG. - 1420-8008 .- 1421-9824. ; 15:1, s. 44-54
-
Tidskriftsartikel (refereegranskat)abstract
- The costs and consequences of donepezil versus placebo treatment in patients with mild to moderate Alzheimer’s disease (AD) were evaluated as part of a 1-year prospective, double-blind, randomized, multinational clinical trial. Patients received either donepezil (n = 142; 5 mg/day for 28 days followed by 10 mg/day according to the clinician’s judgement) or placebo (n = 144). Unit costs were assessed in 1999 Swedish kronas (SEK) and converted to US dollars (USD). Donepezil-treated patients gained functional benefits relative to placebo on the Progressive Deterioration Scale (p = 0.042) and Instrumental Activities of Daily Living scale (p = 0.025) at week 52. Caregivers of donepezil-treated patients spent an average of 400 h less annually providing care than caregivers of placebo-treated patients. Mean annual healthcare costs were SEK 137,752 (USD 16,438) per patient for the donepezil group and SEK 135,314 (USD 16,147) in the placebo group. With the average annual cost of donepezil at SEK 10,723 (USD 1,280) per patient, the SEK 2,438 (USD 291) cost difference represented a 77% cost offset. When caregiver time and healthcare costs were included, mean annual costs were SEK 209,244 (USD 24,969) per patient in the donepezil group and SEK 218,434 (USD 26,066) in the placebo group, a total saving associated with donepezil treatment of SEK 9,190 (USD 1,097) per patient [95% CI of SEK –43,959 (USD –5,246), SEK 25,581 (USD 3,053); p = 0.6]. The positive effects on the efficacy outcome measures combined with no additional costs from a societal perspective indicate that donepezil is a cost-effective treatment, representing an improved strategy for the management of patients with AD.
|
|
| 9. |
- Winblad, B, et al.
(författare)
-
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
- 2001
-
Ingår i: Neurology. - : Ovid Technologies (Wolters Kluwer Health). - 0028-3878 .- 1526-632X. ; 57:3, s. 489-495
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: To evaluate the long-term clinical efficacy and safety of donepezil versus placebo over 1 year in patients with mild to moderate AD.Methods: Patients (n = 286; mean age, 72.5 years) with possible or probable AD from five Northern European countries were randomized to receive either donepezil (n = 142; 5 mg/day for 28 days, followed by 10 mg/day) or placebo (n = 144) for 1 year.Results: The study was completed by 66.9% of the donepezil- and 67.4% of the placebo-treated patients. The benefit of donepezil over placebo was demonstrated by the Gottfries-Bråne-Steen (a global assessment for rating dementia symptoms) total score at weeks 24, 36, and 52 (p < 0.05) and at the study end point (week 52, last observation carried forward; p = 0.054). Advantages of donepezil over placebo were also observed in cognition and activities of daily living (ADL) assessed by the Mini-Mental State Examination at weeks 24, 36, and 52, and the end point (p < 0.02) and by the Progressive Deterioration Scale at week 52 and the end point (p < 0.05). Adverse events (AE) were recorded for 81.7% of donepezil- and 75.7% of placebo-treated patients, with 7% of donepezil- and 6.3% of placebo-treated patients discontinuing because of AE. Treatment response to donepezil was not predicted by APOE genotype or sex in this population.Conclusion: As the first 1-year, multinational, double-blinded, placebo-controlled study of a cholinesterase inhibitor in AD, these data support donepezil as a well tolerated and effective long-term treatment for patients with AD, with benefits over placebo on global assessment, cognition, and ADL.
|
|
